Thinking differently about neurodevelopmental disorders and autism: Lumping vs. splitting

  • Autism Research
Speaker Evdokia Anagnostou, M.D.
Bloorview Research Institute
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Tea: 4:15 – 5:00pm
Lecture: 5:00 – 6:15pm

Autism Research

Autism Research lectures bring together scientists and scholars to discuss diverse and important topics related to autism.

Video replay of this event will be available shortly. Please check back at a later date.

On September 26, 2018, Evdokia Anagnostou discussed the challenge of rethinking classification systems and diagnostic labels for autism and related neurodevelopmental disorders in light of recent findings from research and clinical studies.

Her talk was part of the Simons Foundation Autism Research lecture series.

About the Lecture

There has been an explosion of discoveries furthering our understanding of the biology and the various presentations of autism spectrum disorder and other neurodevelopmental differences. The excitement from the new understandings is matched by the challenge to rethink our classification systems and diagnostic labels and translate that into meaningful treatments.

In this lecture, Evdokia Anagnostou used evidence from genetics, brain imaging and behavior as well as treatment studies to illustrate this emerging rethinking of neurodevelopmental conditions.

About the Speaker

Evdokia Anagnostou is a child neurologist and senior clinician scientist at Holland Bloorview Kids Rehabilitation Hospital; associate professor in the Department of Pediatrics at the University of Toronto; assistant director of the Bloorview Research Institute and co-lead of the Autism Research Centre. She holds a Canada Research Chair in translational therapeutics in autism spectrum disorder and the Dr. Stuart D. Sims Chair in Autism at Holland Bloorview Kids Rehabilitation Hospital.

Anagnostou’s research focuses on translating genomic and systems biology findings into novel treatments for autism spectrum disorder.

Past Lectures

What do we mean by ‘autism risk genes’?

David Ledbetter, Ph.D.
Chief Clinical Officer, Dascena

Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai

Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital

David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.

Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD

Federico Bolognani, M.D., Ph.D.
Vice President, Head of Clinical Science, Axial Therapeutics

Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh

Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx

Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma

Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.

New research results from the Australian Autism Biobank study

Jake Gratten, Ph.D.Group Leader, Mater Research Institute, The University of Queensland
Adjunct Senior Research Fellow, Institute for Molecular Bioscience
Naomi Wray, Ph.D.National Health and Medical Research Council Leadership Fellow – Group Leader, Institute for Molecular Bioscience
Affiliate Professor, Queensland Brain Institute, The University of Queensland

Jake Gratten and Naomi Wray presented findings from the Australian Autism Biobank study, an initiative to establish an Australian resource of biospecimens, phenotypes and genomic data for autism research.

Subscribe to our newsletter and receive SFARI funding announcements and news